Join
Live feed
·
INSIDERFilingvia Quantisnow
Avalo Therapeutics Inc. logo

Chief Financial Officer Sullivan Christopher Ryan sold $222,589 worth of shares (16,915 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 98% to 423 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
AVTX· Avalo Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVTX (Avalo Therapeutics Inc.) and more on Quantisnow.